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Gregory L. Moneta, MD, Section EditorInhibitory Effects of Calcitonin Gene-Related Peptides on Experimen-
tal Vein Graft Disease
Zhang X, Zhuang J, Wu H, et al. Ann Thorac Surg 2010;90:117-23.
Conclusion: Transfection of calcitonin gene-related peptide inhibits
inflammatory mediator expression, macrophage infiltration, and neointimal
hyperplasia in experimental vein graft disease.
Summary: The mechanisms of intimal hyperplasia are complex, and
include interactions with inflammatory cells, inflammatory mediators, and
smooth muscle cells. In particular, macrophages appear necessary for the
initiation of intimal hyperplasia. Calcitonin gene-related peptide (CGRP) is
a biologically active amino peptide, 37 amino acids in length. Studies have
shown that CGRP can inhibit inflammatory cells and expression of inflam-
matory mediators such as tumor necrosis factor (TNF)- and NCP-1 that
appear important in intimal hyperplasia (Li W, et al, Am J Cell Physiol
2006;291:C456-65). CGRP can also inhibit hyperplasia of vascular smooth
muscle and protect endothelial cell function (Deng W, et al, Life Sci
2006;78:1830-8 and Ye F, et al, Vasc Pharm 2007;46:238-46). The authors
sought to evaluate the effects of CGRP expressed by an adeno-associated
virus vector (AAV2) gene transfer on macrophage infiltration and inflam-
matory mediators of vein graft disease in a rabbit model. The hypothesis was
that the transfected CGRP gene could inhibit macrophage infiltration and
expression of inflammatory mediators and thus suppress intimal hyperplasia.
Rabbit jugular vein grafts were incubated ex vivo in a solution of
adeno-associated virus vectors containing the CGRP gene (AAV2/
1.CGRP) or Escherichia coli B-galactosidase (LacZ), or a saline solution.
These grafts were then interposed in the carotid artery. CGRP gene expres-
sion was identified by a reverse transcription polymerase chain reaction
(PCR) and LacZ gene expression was identified by X-gal staining. At 4
weeks, intima/media ratios were determined, and macrophages were iden-
tified with CD68 antibody immunochemistry. Inflammatorymediators were
measured with real-time PCR. CGRP and LacZ gene expression were
positive at 4 weeks postoperatively. The intima/media ratio was significantly
inhibited in the AAV2/1.CGRP group. Also significantly inhibited in the
AAV2/1.CGRP group were monocyte chemoattractant protein-1, TNF-,
inducible nitric oxide synthase, and matrix metalloproteinase-9. Macro-
phage infiltration was also inhibited.
Comment: The authors’ experiment supported their hypothesis. The
report is brief and does not delineate specific patterns of gene expression and
thus does not allow precise determination of mechanism. However, the end
result—very effective inhibition of intimal hyperplasia—is interesting. Vas-
cular and cardiovascular surgeons remember the recent disappointments of
the PREVENT 3 and PREVENT 4 trials, where novel therapy directed at
the genetic level failed to suppress intimal hyperplasia. With respect to
inhibiting intimal hyperplasia, the chiasm between promising basic bench
research and clinical relevance in humans remains wide. This is interesting
work, but given the history of this field, any optimism should be tempered
with caution.
Leiomyosarcoma of the Inferior Vena Cava: Clinicopathologic Study of
40 Cases
Laskin WB, Fanburg-Smith JC, Burke AP, et al. Am J Surg Pathol 2010;34:
1873-81.
Conclusion: Macroscopic resection of a localized vena cava leiomyo-
sarcoma is the best chance for long-term survival. Suprahepatic tumors are
associated with early death, and compromised liver function correlates with
overall poor survival.
Summary: Leiomyosarcoma is the most common sarcoma that affects
the venous system, and nearly 50% arise in the inferior vena cava (Kavorkian
J, Cento DP, Surgery 1973;73:390-400). However, leiomyosarcoma of the
inferior vena cava accounts for only about 0.5% of adult soft tissue sarcomas
(Hollebeck ST, et al, J Am Coll Surg 2003;197:575-9). Overall prognosis is
thought to be poor, with metastatic disease occurring primarily to liver and
lung, and recurrent disease contributing to tumor-related mortality as well.
In this report, the authors detailed the clinical pathologic features and
follow-up data on 40 patients with inferior vena cava leiomyosarcoma. The
study cohort consisted of 31 women and 9 men (mean age, 53 years) whose
material was accessioned to the Armed Forces Institute of Pathology be-
tween 1976 and 2008. Median tumor size was 8.5 cm (range, 2.5-15.0 cm).
The middle segment of the inferior vena cava was most often involved. Most
tumors grew extraluminally. Eleven of the 33 patients managed by complete
radical resection had involved surgical margins. Twenty of 34 patients with
clinical follow-up died of sarcoma-related complications, and 26% died of
unknown causes. Survival rates after resection without documented residual
1420macroscopic disease were 50% at 5 years and 22% at 10 years. Factors that
statistically correlated with death at 2 years were suprahepatic vena cava
involvement, right atrial involvement, predominantly intraluminal tumor
growth, and residual postsurgical macroscopic disease. Univariate analysis
suggested intraluminal tumor (P .03), liver entry or failure (P .01), and
moderate to poor tumor differentiation (P  .03) were associated with
increased tumor-related mortality. On multivariate analysis, only compro-
mised liver function (P  .01) correlated with mortality.
Comment: This is a very large series of leiomyosarcoma of the inferior
vena cava and confirms a poor prognosis associated with these tumors and
the seemingly obvious fact that incomplete resection is associated with a
poor short-term survival. Nevertheless, it is interesting to note that the
growth pattern extraluminal vs intraluminal and the status of the patient’s
overall hepatic function also appear to be important prognostic factors in
patients with this rare malignancy.
Randomized Clinical Trial of VNUS®ClosureFAST™Radiofrequency
Ablation versus Laser for Varicose Veins
Shepherd AC, Gohel MS, Brown LC, et al. Br J Surg 2010;97:810-8.
Conclusion: Radiofrequency ablation (RFA) using VNUS Closure-
FAST (VNUS Medical Technologies, San Jose, Calif) is associated with less
postprocedural pain than endovenous laser ablation (EVLA). Clinical and
quality of life improvements for the two procedures are similar at 6 weeks.
Summary: Endovenous ablative procedures have largely replaced stan-
dard saphenous stripping for treatment of saphenous reflux in patients with
primary varicose veins. At the time of publication of this article, only one
small randomized trial has compared VNUS ClosureFAST and EVLA
(Almeida JI et al, J Vasc Interv Radiol 2009;20:752-9). This current study
compares the most utilized technique for EVLA in Great Britain (980-nm
wavelength and bare fiber) vs the most popular RFA system in Great Britain
(VNUS ClosureFAST). Consecutive patients with primary great saphenous
vein reflux were randomized to EVLA or RFA at a single center. The primary
outcome measure was postprocedural pain at 3 days. Secondary outcome
measures were quality of life at 6 weeks, as determined by the Aberdeen
Varicose Vein Questionnaire (AVVQ) and Short Form 12 (SF-12), and
clinical improvement using the Venous Clinical Severity Score (VCSS).
Analysis was on an intention-to-treat basis. There were 64 patients random-
ized to EVLA and 67 to RFA. At 3 days, mean (SD) pain scores were 26.4
(22.1) mm for RFA and 36.8 (22.5) mm for EVLA (P  .010). Over 10
days, mean (SD) pain scores were 22.0 (19.8) mm for RFA vs 34.3 (21.1)
mm for EVLA respectively (P  .001). Mean number of analgesic tablets
used over 3 days and over 10 days was lower for RFA (P .003) than EVLA
(P .001). There were no differences in AVVQ, SF-12, and VCSS scores at
6 weeks between the two groups (P  .887, P  .076, P  .449, respec-
tively).
Comment: The study demonstrated that VNUS ClosureFAST results
in significantly less pain than 980-nm EVLA for ablation of the great
saphenous veins in treatment of patients with varicose veins. The study
supports previous publications that demonstrate less postprocedural pain
after RFA but failed to show differences in outcomes after 1 month (Mor-
risson N, Semin Vasc Surg 2005;18:15-8 and Almeida J, et al, J Vasc Interv
Radiol 2009;20:752-9). However, EVLA is continuing to be refined. There
are newer fibers with longer wave lengths and jacketed laser fibers that
appear to be associated with lower postintervention pain scores (Almeida J,
et al. Vasc Endovasc Surg 2009;43:467-72). Data comparing these new
devices with VNUS closure system will also eventually be required.
Recurrent Deep Vein Thrombosis: Long-Term Incidence and Natural
History
Labropoulos N, Jen J, Jen H, et al. Ann Surg 2010;251:749-53.
Conclusion: Deep vein thrombosis (DVT) recurrence is associated
with age65 and an elevated residual thrombus burden. Pulmonary embo-
lism (PE) occurs frequently and is a common cause of death.
Summary: The reported incidence of recurrent venous thromboem-
bolism (VTE) is up to 40% at 10 years (Prandoni P, Hematologica 2007;
92:199-205), with most recurrent VTE occurring after anticoagulation has
been discontinued. Whereas much is known about recurrent DVT, there are
actually few long-term studies examining factors influencing recurrent DVT
and its natural history. The authors enrolled both inpatients and outpatients
with acute DVT in their study. They excluded patients with previous VTE,
active cancer, those already on anticoagulation, or those requiring perma-
nent anticoagulation. Also excluded were patients with short life expectancy
